Safety of biweekly α1-antitrypsin treatment in the RAPID programme
Timm Greulich, Jan Chlumsky, Marion Wencker, Oliver Vit, Michael Fries, Thomas Chung, Amgad Shebl, Claus Vogelmeier, Kenneth R Chapman, Noel G McElvaney, RAPID Trial Group, J G W Burdon, R Edwards, A Glanville, M Holmes, P Thompson, M Philipps, P A Wark, R T Abboud, K R Chapman, R K Elwood, P Hernandez, J Chlumsky, N Seersholm, T Skjold, A Altraja, R Mäkitaro, J Ficker, J F Herth, K Schulze, H Teschler, N G McElvaney, J Chorostowska-Wynimko, M Sanak, A Szczeklik, W Z Tomkowsk, P I Stoicescu, T Martynenko, E Piitulainen, M Campos, T J Craig, R A Sandhaus, J M Stocks, Timm Greulich, Jan Chlumsky, Marion Wencker, Oliver Vit, Michael Fries, Thomas Chung, Amgad Shebl, Claus Vogelmeier, Kenneth R Chapman, Noel G McElvaney, RAPID Trial Group, J G W Burdon, R Edwards, A Glanville, M Holmes, P Thompson, M Philipps, P A Wark, R T Abboud, K R Chapman, R K Elwood, P Hernandez, J Chlumsky, N Seersholm, T Skjold, A Altraja, R Mäkitaro, J Ficker, J F Herth, K Schulze, H Teschler, N G McElvaney, J Chorostowska-Wynimko, M Sanak, A Szczeklik, W Z Tomkowsk, P I Stoicescu, T Martynenko, E Piitulainen, M Campos, T J Craig, R A Sandhaus, J M Stocks
Abstract
Administration of 120 mg·kg−1 α1-antitrypsin on a biweekly basis was safe and well tolerated http://ow.ly/CVbz30lUBum
Trial registration: ClinicalTrials.gov NCT00261833 NCT00670007.
Conflict of interest statement
Conflict of interest: T. Greulich reports personal fees from AstraZeneca and GSK (lecture fees), Boehringer-Ingelheim, Chiesi, CSL Behring and Novartis (lecture fees, advisory board and travel support), and Mundipharma (lecture fees and advisory board); and grants and personal fees from Grifols (AATD-Labor, lecture fees and travel support), all outside the submitted work. Conflict of interest: J. Chlumsky reports honoraria for lectures organised by CSL Behring, and for lectures organised by Boehringer Ingelheim, outside the submitted work. Conflict of interest: M. Wencker reports support from conresp as a consultant to CSL Behring, during the conduct of the study. Conflict of interest: O. Vit reports support from CSL Behring, as employer and sponsor of the study. Conflict of interest: M. Fries reports support from CSL Behring, as employer and sponsor of the study. Conflict of interest: T. Chung reports support from CSL Behring, as employer and sponsor of the study. Conflict of interest: A. Shebl reports support from CSL Behring, as employer and sponsor of the study. Conflict of interest: C. Vogelmeier reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols and Novartis; personal fees from CSL Behring, Chiesi, Menarini, Mundipharma, Teva and Cipla; and grants from Bayer-Schering, MSD and Pfizer, all outside the submitted work. Conflict of interest: K.R. Chapman reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, CSL Behring, Grifols, Sanofi, Genentech, Kamada, Roche and Novartis; grants from Baxter, GlaxoSmithKline, Amgen, Shire and Octapharma; personal fees from Merck; and the CIHR-GSK Research Chair in Respiratory Health Care Delivery, UHN, all during the conduct of the study. Conflict of interest: N.G. McElvaney reports research grants for carrying out the original RAPID and RAPID OLE studies from CSL Behring, during the conduct of the study; and personal fees from CSL Behring (advisory board), outside the submitted work.
Figures
References
- Greene CM, Marciniak SJ, Teckman J, et al. . α1-Antitrypsin deficiency. Nat Rev Dis Primers 2016; 2: 16051.
- Gadek JE, Klein HG, Holland PV, et al. . Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981; 68: 1158–1165.
- Piras B, Ferrarotti I, Lara B, et al. . Clinical phenotypes of Italian and Spanish patients with α1-antitrypsin deficiency. Eur Respir J 2013; 42: 54–64.
- Greulich T, Nell C, Herr C, et al. . Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015. Orphanet J Rare Dis 2016; 11: 75.
- Chapman KR, Burdon JG, Piitulainen E, et al. . Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386: 360–368.
- McElvaney NG, Burdon J, Holmes M, et al. . Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med 2017; 5: 51–60.
- American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168: 818–900.
- Sandhaus RA, Turino G, Brantly ML, et al. . The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis 2016; 3: 668–682.
- Miravitlles M, Dirksen A, Ferrarotti I, et al. . European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency. Eur Respir J 2017; 50: 1700610.
- Vidal R, Blanco I, Casas F, et al. . Diagnóstico y tratamiento del déficit de alfa-1-antitripsina [Guidelines for the diagnosis and management of alpha-1 antitrypsin deficiency]. Arch Bronconeumol 2006; 42: 645–659.
- Dirksen A, Dijkman JH, Madsen F, et al. . A randomized clinical trial of α1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160: 1468–1472.
- Campos MA, Kueppers F, Stocks JM, et al. . Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK). COPD 2013; 10: 687–695.
- Barker AF, Iwata-Morgan I, Oveson L, et al. . Pharmacokinetic study of α1-antitrypsin infusion in α1-antitrypsin deficiency. Chest 1997; 112: 607–613.
- Tortorici MA, Rogers JA, Vit O, et al. . Quantitative disease progression model of α-1 proteinase inhibitor therapy on computed tomography lung density in patients with α-1 antitrypsin deficiency. Br J Clin Pharmacol 2017; 83: 2386–2397.
- Sorrells S, Camprubi S, Griffin R, et al. . SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency. Respir Med 2015; 109: 490–499.
Source: PubMed